Q3 2017 EPS Estimates for Aimmune Therapeutics, Inc. (AIMT) Decreased by Wedbush
Aimmune Therapeutics, Inc. (NASDAQ:AIMT) – Stock analysts at Wedbush dropped their Q3 2017 earnings per share estimates for shares of Aimmune Therapeutics in a research note issued on Monday. Wedbush analyst L. Moussatos now forecasts that the biotechnology company will post earnings of ($0.72) per share for the quarter, down from their previous estimate of ($0.69). Wedbush has a “Ourperform” rating and a $42.00 price objective on the stock. Wedbush also issued estimates for Aimmune Therapeutics’ Q4 2017 earnings at ($0.83) EPS, FY2017 earnings at ($2.72) EPS, FY2018 earnings at ($3.50) EPS, FY2019 earnings at ($3.58) EPS, FY2020 earnings at ($1.31) EPS and FY2021 earnings at $2.78 EPS.
Other equities research analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of Aimmune Therapeutics from a “sell” rating to a “buy” rating and set a $21.00 price target for the company in a research report on Tuesday, May 16th. ValuEngine raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 13th. BidaskClub cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Finally, Piper Jaffray Companies set a $38.00 price target on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Thursday, July 27th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $33.00.
Aimmune Therapeutics (NASDAQ AIMT) opened at 19.31 on Wednesday. The firm’s 50 day moving average is $20.90 and its 200-day moving average is $20.00. The company’s market cap is $975.83 million. Aimmune Therapeutics has a 52 week low of $12.38 and a 52 week high of $27.31.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by $0.01.
A number of large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC purchased a new stake in Aimmune Therapeutics during the fourth quarter worth approximately $2,100,000. Norges Bank purchased a new stake in Aimmune Therapeutics during the fourth quarter worth approximately $1,258,000. Teachers Advisors LLC boosted its stake in Aimmune Therapeutics by 2.4% in the fourth quarter. Teachers Advisors LLC now owns 43,229 shares of the biotechnology company’s stock worth $884,000 after buying an additional 1,025 shares during the last quarter. Columbus Circle Investors purchased a new stake in Aimmune Therapeutics during the first quarter worth approximately $897,000. Finally, Nationwide Fund Advisors boosted its stake in Aimmune Therapeutics by 23.7% in the first quarter. Nationwide Fund Advisors now owns 20,095 shares of the biotechnology company’s stock worth $437,000 after buying an additional 3,851 shares during the last quarter. 69.65% of the stock is owned by institutional investors.
In related news, insider Douglas T. Sheehy sold 7,460 shares of the stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $21.66, for a total transaction of $161,583.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Susan E. Barrowcliffe sold 6,110 shares of the stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $22.00, for a total transaction of $134,420.00. Following the sale, the insider now directly owns 960 shares of the company’s stock, valued at approximately $21,120. The disclosure for this sale can be found here. Insiders sold a total of 188,470 shares of company stock valued at $3,942,092 in the last ninety days. Corporate insiders own 24.56% of the company’s stock.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.